Companies › Sonoma Biotherapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SBT777101 | – | Phase 1 | Hidradenitis Suppurativa; Rheumatoid Arthritis | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06361836 | SBT777101 | Phase 1 | Hidradenitis Suppurativa | Immunology | Nov 2026 |
| NCT06201416 | SBT777101 | Phase 1 | Rheumatoid Arthritis | Immunology | Nov 2026 |
Cash of $5m on 2026-06-30; operating cash outflow about $3m a year; runway about 24 months at that burn, to Jul 2028
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.